Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
NCT04425551 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2026-01-02
Summary
The modern treatment of meibomian gland dysfunction(MGD) is based on anti-inflammatory drops or oral antibiotics for decreasing dry eye disease (DED) associated inflammation, warm compresses for liquefying the thicker meibum, and lid hygiene for reducing the bacterial overload. But, such treatments have shown limited effectiveness to a large proportion of patients with MGD, due to the multifactorial background of the disease. Thus, alternative approaches aiming at different aspects of the DED pathophysiology are needed.
Elimination of posterior lid-margin hyperemia with telangiectasia could be a treatment target for reducing the secretion of inflammatory mediators in the course of MGD. Using the mechanism of photocoagulation via selective thermolysis, laser light could contribute to the destruction of abnormal vessels at the posterior lid-margin and thus, the reduction of inflammation. Recently, sub-threshold (micropulse) laser photocoagulation was introduced in ophthalmology and offers significant clinical advantages compared to conventional continuous wave (CW) approach, preventing laser induced thermal damage and related treatment side effects.
This study investigates the effect of sub-threshold (micropulse) laser treatment for dry eye disease due to meibomian gland dysfunction combined with increased eyelid margin vascularity.
Conditions
- Dry Eye
- Dry Eye Syndromes
- Meibomian Gland Dysfunction
Interventions
- PROCEDURE
-
laser light
laser photocoagulation of the telangiectatic vessels of the lower eyelid margin with a slit lamp-based 532 nm optically pumped dual- diode solid-state subthreshold (SP-Mode) laser system
- DEVICE
-
Sham treatment
Sham treatment replicated all procedural steps (eyelid eversion, stabilization, slit-lamp aiming, equivalent spot count) using identical laser settings, but with minimal power (50 mW, duration 10 ms) and beam offset to the adjacent non-vascular periorbital skin, ensuring no energy delivery to eyelid margin vessels, and preserving the device operational sound, laser light, and foot pedal activation. No laser energy was delivered to eyelid margin vasculature in the sham treatment, and no visible tissue reaction or blanching was observed during the procedure. The anesthesia and cleaning procedures were identical.
Sponsors & Collaborators
-
National and Kapodistrian University of Athens
collaborator OTHER -
Naval Hospital, Athens
lead OTHER
Principal Investigators
-
Nikolaos Kappos, MD · Naval Hospital, Athens
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-12-06
- Primary Completion
- 2025-04-03
- Completion
- 2025-07-18
Countries
- Greece
Study Locations
More Related Trials
-
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
NCT02621593 ·Status: COMPLETED ·Phase: NA
-
Observe the Effects of Far Infrared Eye Masks on Acupoints Around the Eyes in Patients With Dry Eye Syndrome
NCT07060131 ·Status: COMPLETED ·Phase: NA
-
Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity
NCT02992535 ·Status: UNKNOWN ·Phase: PHASE4
-
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
NCT03396913 ·Status: COMPLETED ·Phase: NA
-
Intense Pulsed Light Therapy in Meibomian Gland Dysfunction
NCT04904874 ·Status: UNKNOWN ·Phase: NA
-
Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction
NCT03518398 ·Status: COMPLETED ·Phase: PHASE3
-
Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate
NCT01692652 ·Status: COMPLETED ·Phase: NA
-
Intense Regulated Pulse Light Therapy in Dry Eye Disease
NCT05553561 ·Status: UNKNOWN ·Phase: NA
-
Treating Meibomian Gland Disease in a Pediatric Population
NCT07229001 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction
NCT02618304 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device
NCT03788486 ·Status: WITHDRAWN ·Phase: NA
-
Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
NCT03658811 ·Status: COMPLETED ·Phase: NA
-
The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression
NCT05713981 ·Status: COMPLETED ·Phase: NA
-
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
NCT01521507 ·Status: COMPLETED ·Phase: NA
-
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
NCT03956225 ·Status: COMPLETED ·Phase: NA
-
Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction
NCT01600625 ·Status: COMPLETED ·Phase: NA
-
The Effect of Meibomian Glands Massage on Signs and Symptoms of Dry Eye
NCT03104894 ·Status: COMPLETED ·Phase: NA
-
EyeBag Effectiveness in Meibomian Gland Dysfunction
NCT01870180 ·Status: COMPLETED ·Phase: NA
-
Meibomian Gland Dysfunction Treatment
NCT04229888 ·Status: COMPLETED ·Phase: NA
-
Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
NCT00832130 ·Status: COMPLETED ·Phase: NA
-
Efficiency and Changes of Cytokines Expression in Tear After Intense Pulsed Light Treating Dry Eye Disease
NCT04165785 ·Status: COMPLETED ·Phase: NA
-
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
NCT02965846 ·Status: TERMINATED ·Phase: PHASE3
-
iLux Treatment for Meibomian Gland Dysfunction (MGD)
NCT03055650 ·Status: COMPLETED ·Phase: NA
-
Investigating the Effect of At Home Thermal Therapy on Dry Eye Patients With Meibomian Gland Dysfunction
NCT03291704 ·Status: UNKNOWN ·Phase: NA
-
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
NCT02102464 ·Status: COMPLETED ·Phase: NA